SCHEDULE: Legion Partners Boosts Stake in Lifecore Biomedical

Legion Partners, through various entities, has increased its beneficial ownership of Lifecore Biomedical, Inc. to 17.1%, signaling a significant investment and potential strategic interest.

Summary

• Legion Partners, along with its affiliated entities (Legion Partners I, II, LLC, Asset Management, Holdings), has increased its beneficial ownership in Lifecore Biomedical, Inc. to 17.1%.
• This filing is an amendment to a previous Schedule 13D, reflecting changes in beneficial ownership.
• The total number of shares beneficially owned by Legion Partners Holdings, LLC is 6,794,595, representing 17.1% of the outstanding shares.
• This ownership includes shares directly held, shares issuable upon conversion of Series A Preferred Stock, and restricted stock units (RSUs) granted to Christopher S. Kiper.
• Legion Partners I and II have initiated the redemption of their Series A Preferred Stock, with the Issuer required to redeem these shares by December 28, 2026.
• Christopher S. Kiper and Raymond T. White, as managing directors/members of the Legion Partners entities, are also listed as beneficial owners.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating significant investor interest but also highlighting a potential future cash obligation for the company due to stock redemption.

Positives

• Increased beneficial ownership by Legion Partners to 17.1% indicates strong conviction in Lifecore Biomedical's value.
• The conversion of Series A Preferred Stock into common shares and the potential vesting of RSUs suggest a growing stake and alignment of interests.
• Christopher S. Kiper's directorship on the Board of Directors provides a channel for engagement and oversight.

Negatives

• The redemption of Series A Preferred Stock by Legion Partners I and II, with the Issuer obligated to pay cash by December 28, 2026, could represent a future cash outflow for Lifecore Biomedical.
• The disclaimer of beneficial ownership for securities not directly owned by each reporting person suggests a complex ownership structure and potential for differing interpretations of control.

Risks

• The redemption of Series A Preferred Stock by Legion Partners I and II requires Lifecore Biomedical to pay a significant cash amount by December 28, 2026, which could strain liquidity if not managed effectively.
• The substantial ownership stake by Legion Partners could lead to activist investor actions or pressure on management regarding strategic decisions.
• The RSUs granted to Mr. Kiper, while economically benefiting Legion Partners Asset Management, are tied to his board service, creating a potential conflict if his board duties diverge from the company's best interests.

Future Outlook

The redemption of Series A Preferred Stock by Legion Partners I and II is scheduled for December 28, 2026, which will require the Issuer to make a cash payment. Certain RSUs granted to Mr. Kiper are scheduled to vest within the next 60 days and in calendar year 2026 and 2027.

Management Comments

• Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

Industry Context

StockSavvy.ai notes that increased beneficial ownership filings, particularly by investment firms like Legion Partners, often signal a heightened level of engagement with the target company, potentially leading to strategic discussions or activist campaigns within the biotechnology and medical device sector.

Management Changes

Related Party Transactions

• Christopher S. Kiper, as a director, has been granted RSUs. The economic interests in these RSUs are transferred to Legion Partners Asset Management for no consideration, as Mr. Kiper serves as a representative of Legion Partners.

Stakeholder Impact

• Shareholders: Increased stake by a significant investor may lead to strategic changes or activist pressure, potentially impacting share value.
• Creditors/Lenders: The upcoming redemption of Series A Preferred Stock by December 28, 2026, represents a significant cash outflow for Lifecore Biomedical, which could impact its financial flexibility and debt covenants.
• Management: Increased scrutiny and potential pressure from a large, engaged shareholder.

Next Steps

• Lifecore Biomedical is required to redeem the Series A Preferred Stock held by Legion Partners I and II by December 28, 2026.
• RSUs granted to Mr. Kiper are scheduled to vest within the next 60 days and in 2026/2027.

Key Dates

Recommendation

The increased stake by Legion Partners suggests a belief in the company's underlying value, but the pending redemption of preferred stock introduces a near-term financial obligation for Lifecore Biomedical. This creates a balance of potential upside from investor engagement and downside risk from the cash requirement, warranting a 'hold' position until further clarity on the company's strategy to manage the redemption.

Keywords

Lifecore Biomedical, Schedule 13D, Legion Partners, Beneficial Ownership, Series A Preferred Stock, Restricted Stock Units, Christopher S. Kiper, Investment, SEC Filing, Amendment